inclusion criteria: 1. male or female adults: ≥ 18 years. 2. must have a clinical diagnosis of covid-19 at least 4 weeks prior to the screening date, with at least one of clinical symptoms (e.g., fever ≥ 38°c, fatigue, cough) and a positive result by the reverse-transcription polymerase chain reaction (rt-pcr) testing or equivalent. 3. experiencing at least two covid-19 respiratory symptoms with a score of two or higher using the fda assessment of 14 common covid-19-related symptoms questionnaire for at least 4 weeks (28 days) after initial positive covid-19 diagnosis: cough, sore throat, runny/stuffy nose, shortness of breath (difficulties breathing), tightness of chest, low exercise tolerance. 4. able to bear weight and ambulate a minimum of 10 meters distance. 5. women of childbearing potential and their partner must agree to use at least one highly effective method of contraception (e.g., hormonal contraceptives \[implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings\], intrauterine devices, bilateral tubal occlusion, or sexual abstinence) for the duration of the study. 6. informed consent obtained from the patient or the patient's legal representative.

inclusion criteria: 1. male or female adults: ≥ 18 years. 2. must have a clinical diagnosis of covid-19 at least 4 weeks prior to the screening date, with at least one of clinical symptoms (e.g., fever ≥ 38°c, fatigue, cough) and a positive result by the reverse-transcription polymerase chain reaction (rt-pcr) testing or equivalent. 3. experiencing at least two covid-19 respiratory symptoms with a score of two or higher using the fda assessment of 14 common covid-19-related symptoms questionnaire for at least 4 weeks (28 days) after initial positive covid-19 diagnosis: cough, sore throat, runny/stuffy nose, shortness of breath (difficulties breathing), tightness of chest, low exercise tolerance. 4. able to bear weight and ambulate a minimum of 10 meters distance. 5. women of childbearing potential and their partner must agree to use at least one highly effective method of contraception (e.g., hormonal contraceptives \[implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings\], intrauterine devices, bilateral tubal occlusion, or sexual abstinence) for the duration of the study. 6. informed consent obtained from the patient or the patient's legal representative.

inclusion criteria: male or female adults: ≥ 18 years. must have a clinical diagnosis of covid-19 at least 4 weeks prior to the screening date, with at least one of clinical symptoms (e.g., fever ≥ 38°c, fatigue, cough) and a positive result by the reverse-transcription polymerase chain reaction (rt-pcr) testing or equivalent. experiencing at least two covid-19 respiratory symptoms with a score of two or higher using the fda assessment of 14 common covid-19-related symptoms questionnaire for at least 4 weeks (28 days) after initial positive covid-19 diagnosis: cough, sore throat, runny/stuffy nose, shortness of breath (difficulties breathing), tightness of chest, low exercise tolerance. able to bear weight and ambulate a minimum of 10 meters distance. women of childbearing potential and their partner must agree to use at least one highly effective method of contraception (e.g., hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], intrauterine devices, bilateral tubal occlusion, or sexual abstinence) for the duration of the study. informed consent obtained from the patient or the patient's legal representative.

inclusion criteria: male or female adults: ≥ 18 years. must have a clinical diagnosis of covid-19 at least 4 weeks prior to the screening date, with at least one of clinical symptoms (e.g., fever ≥ 38°c, fatigue, cough) and a positive result by the reverse-transcription polymerase chain reaction (rt-pcr) testing or equivalent. experiencing at least two covid-19 respiratory symptoms with a score of two or higher using the fda assessment of 14 common covid-19-related symptoms questionnaire for at least 4 weeks (28 days) after initial positive covid-19 diagnosis: cough, sore throat, runny/stuffy nose, shortness of breath (difficulties breathing), tightness of chest, low exercise tolerance. able to bear weight and ambulate a minimum of 10 meters distance. women of childbearing potential and their partner must agree to use at least one highly effective method of contraception (e.g., hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], intrauterine devices, bilateral tubal occlusion, or sexual abstinence) for the duration of the study. informed consent obtained from the patient or the patient's legal representative.

inclusion criteria: 1. male or female adults: ≥ 18 years. 2. must have a clinical diagnosis of covid-19 at least 4 weeks prior to the screening date, with at least one of clinical symptoms (e.g., fever ≥ 38°c, fatigue, cough) and a positive result by the reverse-transcription polymerase chain reaction (rt-pcr) testing or equivalent. 3. experiencing at least two covid-19 respiratory symptoms with a score of two or higher using the fda assessment of 14 common covid-19-related symptoms questionnaire for at least 4 weeks (28 days) after initial positive covid-19 diagnosis: cough, sore throat, runny/stuffy nose, shortness of breath (difficulties breathing), tightness of chest, low exercise tolerance. 4. able to bear weight and ambulate a minimum of 10 meters distance. 5. women of childbearing potential and their partner must agree to use at least one highly effective method of contraception (e.g., hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], intrauterine devices, bilateral tubal occlusion, or sexual abstinence) for the duration of the study. 6. informed consent obtained from the patient or the patient's legal representative.

inclusion criteria: 1. male or female adults: ≥ 18 years. 2. must have a clinical diagnosis of covid-19 at least 4 weeks prior to the screening date, with at least one of clinical symptoms (e.g., fever ≥ 38°c, fatigue, cough) and a positive result by the reverse-transcription polymerase chain reaction (rt-pcr) testing or equivalent. 3. experiencing at least two covid-19 respiratory symptoms with a score of two or higher using the fda assessment of 14 common covid-19-related symptoms questionnaire for at least 4 weeks (28 days) after initial positive covid-19 diagnosis: cough, sore throat, runny/stuffy nose, shortness of breath (difficulties breathing), tightness of chest, low exercise tolerance. 4. able to bear weight and ambulate a minimum of 10 meters distance. 5. women of childbearing potential and their partner must agree to use at least one highly effective method of contraception (e.g., hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], intrauterine devices, bilateral tubal occlusion, or sexual abstinence) for the duration of the study. 6. informed consent obtained from the patient or the patient's legal representative.